GeoVax Advances GEO-MVA to Phase 3 for Mpox Response, Expanding Global MVA Supply
GeoVax Labs endorsed WHO’s call to sustain mpox response as its GEO-MVA vaccine advances to regulatory execution to expand MVA supply beyond the sole current manufacturer. The company plans a Phase 3 bypassing Phase 1/2 under EMA guidance to bolster global vaccine capacity and address chronic supply constraints.
1. Endorsement of Sustained Mpox Response
GeoVax Labs publicly supported the call that the mpox epidemic remains active, highlighting ongoing transmission, viral evolution and disproportionate impacts in under-resourced regions. The company emphasized that complacency risks future outbreaks and urged sustained political will, financing and diversified countermeasure access.
2. GEO-MVA Program Progress
GEO-MVA, a Modified Vaccinia Ankara–based vaccine candidate, has a defined regulatory pathway and is transitioning from planning to execution. Based on recent EMA guidance, GeoVax intends to advance directly to a global Phase 3 trial, omitting earlier phases to accelerate readiness.
3. Expanding Global MVA Supply
GeoVax aims to reduce dependence on a single licensed MVA manufacturer by establishing additional, geographically diversified production capacity. This initiative is designed to strengthen long-term public-health and biodefense preparedness by addressing chronic MVA vaccine supply constraints.